Nature Communications (Apr 2022)
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
- Michiel S. van der Heijden,
- Thomas Powles,
- Daniel Petrylak,
- Ronald de Wit,
- Andrea Necchi,
- Cora N. Sternberg,
- Nobuaki Matsubara,
- Hiroyuki Nishiyama,
- Daniel Castellano,
- Syed A. Hussain,
- Aristotelis Bamias,
- Georgios Gakis,
- Jae-Lyun Lee,
- Scott T. Tagawa,
- Ulka Vaishampayan,
- Jeanny B. Aragon-Ching,
- Bernie J. Eigl,
- Rebecca R. Hozak,
- Erik R. Rasmussen,
- Meng Summer Xia,
- Ryan Rhodes,
- Sameera Wijayawardana,
- Katherine M. Bell-McGuinn,
- Amit Aggarwal,
- Alexandra Drakaki
Affiliations
- Michiel S. van der Heijden
- The Netherlands Cancer Institute
- Thomas Powles
- Barts Cancer Institute, Queen Mary University of London
- Daniel Petrylak
- Smilow Cancer Hospital at Yale New Haven, Yale New Haven Hospital
- Ronald de Wit
- Erasmus MC Cancer Institute
- Andrea Necchi
- Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital
- Cora N. Sternberg
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital
- Nobuaki Matsubara
- National Cancer Center Hospital East
- Hiroyuki Nishiyama
- University of Tsukuba
- Daniel Castellano
- Hospital Universitario 12 de Octubre
- Syed A. Hussain
- University of Sheffield, Department of Oncology and Metabolism
- Aristotelis Bamias
- National and Kapodistrian University of Athens
- Georgios Gakis
- University Hospital of Würzburg
- Jae-Lyun Lee
- Asan Medical Center, Urologic Cancer Center
- Scott T. Tagawa
- Weill Cornell Medical College, Department of Genitourinary Oncology
- Ulka Vaishampayan
- University of Michigan Ann Arbor
- Jeanny B. Aragon-Ching
- Inova Schar Cancer Institute
- Bernie J. Eigl
- BC Cancer
- Rebecca R. Hozak
- Eli Lilly and Company
- Erik R. Rasmussen
- Eli Lilly and Company
- Meng Summer Xia
- Eli Lilly and Company
- Ryan Rhodes
- Eli Lilly and Company
- Sameera Wijayawardana
- Eli Lilly and Company
- Katherine M. Bell-McGuinn
- Eli Lilly and Company
- Amit Aggarwal
- Eli Lilly and Company
- Alexandra Drakaki
- David Geffen School of Medicine, Division of Hematology and Oncology, UCLA
- DOI
- https://doi.org/10.1038/s41467-022-29441-y
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
Identification of biomarkers to stratify patients who might benefit from treatment is needed to optimize targeted therapies. Here, based on an analysis of the RANGE trial (NCT02426125), the authors report potentially predictive biomarkers for survival benefit in patients with platinum-refractory advanced urothelial carcinoma treated with the anti-VEGFR2 monoclonal antibody ramucirumab.
